Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.

Cancer chemotherapy and pharmacology - 1 Oct 2015

De Iuliis Francesca, Salerno Gerardo, Taglieri Ludovica, Scarpa Susanna

Abstract excerpt

PURPOSE: Breast cancer is a heterogeneous disease, characterized by various molecular phenotypes that correlate with different prognosis and response to treatments. Taxanes are some of the most active chemotherapeutic agents for breast cancer; however, their utilization is limited, due to hematologic and cumulative neurotoxicity on treated patients. To understand why only some patients experience severe adverse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Bridged-Ring Compounds

Share to Cytochrome P-450 CYP1B1

Share to Evidence-Based Medicine

Share to Pharmacogenetics

Share to Taxoids

Source

Identifiers

PMID: 26198313
DOI: 10.1007/s00280-015-2818-4

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.PMID 26198313Read ↗

Novel molecular biomarkers associated with Taxane-induced toxicities in women with breast cancer from the Brazilian Amazon.Semantic proximity Read ↗

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer ChemotherapySemantic proximity Read ↗

Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.Semantic proximity Read ↗

Pharmacogenomics in breast cancer: current trends and future directions.Semantic proximity Read ↗

Single Nucleotide Polymorphisms as the Efficient Prognostic Markers in Breast Cancer.Semantic proximity Read ↗

Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.Semantic proximity Read ↗

Genomics and pharmacogenomics of breast cancer: current knowledge and trends.Semantic proximity Read ↗

Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.Semantic proximity Read ↗

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patientsSemantic proximity Read ↗

Predictive value of two polymorphisms in ABCB1, rs1045642 and rs1128503, in prognosis following taxane-containing chemotherapy: A meta-analysisSemantic proximity Read ↗

Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer PatientsSemantic proximity Read ↗

Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and EfficacySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.